Apixaban is an oral anticoagulant that selectively inhibits Factor Xa, a crucial enzyme in the blood coagulation cascade. By blocking Factor Xa, apixaban prevents the formation of thrombin, thereby reducing the risk of blood clots. It is commonly prescribed to prevent stroke and systemic embolism in patients with atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban offers a predictable anticoagulant effect with fewer monitoring requirements compared to traditional therapies.
| Catalog Number | A000903 |
| CAS Number | 503612-47-3 |
| Synonyms | 503612-47-3; Eliquis; BMS-562247-01; BMS-562247; BMS 562247-01 |
| Molecular Formula | C25H25N5O4 |
| Purity | ≥95% |
| Target | Thrombin |
| Solubility | >11.5mg/mL in DMSO |
| Storage | -20°C |
| Overview of Clinical Research | Apixaban is factor Xa inhibitor. The phase III study of Apixaban on acute coronary syndromes is ongoing. |
| IUPAC Name | 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide |
| InChI | InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) |
| InChIKey | QNZCBYKSOIHPEH-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N |
